title: 4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study.
abstract: Fifteen patients with advanced epithelial ovarian cancer were treated with 4-demethoxydaunorubicin (IMI-30) after platinum failure. A total of 33 courses of IMI-30 15 mg/m2, per os, daily for 3 consecutive days every 3 weeks were performed. Three patients experienced severe hematologic toxicity (WHO grade greater than or equal to 3), while gastroenteric toxicity was acceptable and no cardiotoxicity was observed. One minor response, 4 stabilization of disease and 7 progression were observed in 12 evaluable patients. In conclusion, IMI-30, at this scheduling, is inactive in our small series of heavily pretreated epithelial ovarian cancer patients.
authors.forename: M
authors.initials: M
authors.lastname: Bruzzone
authors.forename: S
authors.initials: S
authors.lastname: Chiara
authors.forename: A
authors.initials: A
authors.lastname: Falcone
authors.forename: G
authors.initials: G
authors.lastname: Graziani
authors.forename: P F
authors.initials: PF
authors.lastname: Conte
authors.forename: R
authors.initials: R
authors.lastname: Rosso
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015255:Idarubicin; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D015255:Idarubicin; D003630:Daunorubicin